Breast cancer is a common malignancy comprising 24.4% of all cancers and is the leading cause of death among Iranian women (1, 2). Approximately 5-10% of all breast cancers are attributable to the strong hereditary susceptibility, highly penetrant genes, such as BRCA1/2 (3).
www.imaqpress.com reasons including the cost of genetic testing, the low probability of mutations that concerned patients and the psychosocial reasons(8). Breast cancer risk determination plays an important role to select an appropriate strategy of disease management (9). To date, correlation of in vitro heterozygote risk and lifetime risk of breast cancer patients with clinicopathologic features have not been described in Iran population. In this research we estimated the probability of carrying of mutations in BRCA1 by risk evaluation program and correlation between heterozygote risk and lifetime risk of breast cancer patients with age, weight, histological type, menopausal status, lymph node status, histological grade, tumor stage, Diabetes status and expression of five immunohistochemical markers (ER, PR, HER-2, P53 and Ki67) investigated.
Materials and methods Patients:
A study was conducted with 64 Ir anian women diagnosed with breast cancer who were referred to the Ghaem Hospital of Mashhad University of Medical Sciences between 2010 and 2013. After genetic counseling of index cases with breast cancer and obtaining a written informed consent, demographic information, family-history and hormone receptor status of breast cancer patients were archived to a database. The individual's risk of heterozygosity and the lifetime risk for breast cancer were assessed by Cyrillic 3.1 (an established pedigree drawing program designed for clinical geneticist). Data Collection: The patients wer e classified into four age groups: <35 years, 35-49 years, 50-64 years and >65 years. Age of 35 as cut-off point to define young age breast cancer was regarded. A clinical and pathology information such as patient age, weight, histological type, tumor stage, menopausal status, lymph node status, histological grade, ER, PR, HER-2, P53 and Ki67 status were extracted from medical and pathology records.
DNA Extraction and Polymerase Chain Reaction:
Genomic DNA was extracted from peripheral whole blood samples (9 breast or ovarian cancer patients were selected for BRCA1 germline mutations analysis) using standard procedure (salting out). All of 24 exons of BRCA1 gene were amplified by PCR using 34 pairs of exon-specific primers.
PCR was performed using GenetBio kit with the following program: 2 min at 94°C, 30 s at 94°C, 30 s at 54-64°C, and 1 min at 72°C for 35 cycles in a 25 μl reaction volume.
BRCA1 Sequence Analysis
For mutational analysis, PCR products were sequenced using forward or reverse primers by a commercial sequencing company (Macrogen, Korea) and the results was analyzed using SeqScape® Software Version 2.7. Finally, all detected variants were checked by BIC and HGMD database.
Statistical analysis
Statistical analysis was performed using the SPSS 11.0 statistical package (SPSS, Chicago, IL). All data were expressed as mean ± s.d. and analyzed by t test or ANOVA. P-value ≤ 0.05 was considered statistically significant.
Results

Demographic and Clinicopathological Characteristics
In the overall study group, the mean ages ± SD at diagnosis of studied patients was 44.3±10.0 years. 64 patients were diagnosed with unilateral breast cancer that Invasive Ductal Carcinoma (IDC) was the most common form between studied patients and others were comedo carcinoma, infiltrating ductal carcinoma, medullary carcinoma, invasive papillary carcinoma and mucinous carcinoma. Histological grade of the patients were grade 1 (8 cases), grade 2 (27 cases) and grade 3 (18 cases). Tumor stage classification were stage 1 (8 cases), stage II (32 cases), stage III (9 cases) and stage IV (6 cases 
Association between the heterozygote and lifetime risk of breast cancer patients with clinicopathological characteristics
We compared heterozygote and lifetime risk between different groups of population and tumor characteristic features. Our results showed a significant difference between heterozygote risk and lifetime risk of different groups of age (P<0.01). The risk at age 85 was also statistically significant between the two groups of premenopausal and postmenopausal breast cancer patients (P<0.001) ( 
BRCA1 Mutation Analysis
According to inclusion criteria and genetic counseling, nine breast or ovarian cancer patients were analyzed for BRCA1 germline mutations analysis. In patients' pedigree, the information about the proband and the relatives with breast and/or ovarian cancer has been demonstrated (Supplementary 1). Different mutations in BRCA1 gene were identified in the patients (table 5) .
Discussion
Breast cancer (BC) is one of the common cancer between women in worldwide and the top malignancy in Iranian women over the past few decades (10) . It has been reported that the mutation of BRCA1/2 have been found in 2-6% of breast cancer patients (7, 11, 12) . BC at a younger age is also related to the disease advanced stage, higher grade, ER negativity and BRCA1 ectopic expression (13) . In this study we compared the heterozygote risk and lifetime risk between different groups of our population and tumor characteristic features. 45-80% lifetime risk of breast cancer has been estimated in carriers of BRCA1 and BRCA2 mutations (4, 7). In our results heterozygote risk and lifetime risk had a significant difference between diverse groups of age (P<0.01). The risk to age 85 was statistically significant between the two groups of premenopausal and postmenopausal breast cancer patients (P<0.001). Meanwhile, there was no statistically significant difference across the age groups between the heterozygote risk and lifetime risk in breast cancer patients and clinicopathological traits (P>0.05). Association between 20 years risk of breast cancer patients and other clinicopathological characteristics was merely statistically significant for expression of HER-2 and other factor (ER, PR, Ki67 and P53) were not significant. Different studies in Iran demonstrated various alterations of BRCA1 and BRCA2 genes. In our previous study we had introduced a novel mutation in Khorasan papulation (accession number BankIt1473921 JN686490) (14) . However, due to the sequencing of nine patients in present study, not only we found out submitted mutation, but also, no novel mutations did not determine in BRCA1 gene exons.
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Conclusion
Our data recommended which utilization of Cyrillic software for Iranian family would open new sights towards the prediction, prognosis and mutation detection. People with heterozygote risk over 30% are more likely to be infect invasive ductal carcinoma and are a good candidate for the BRCA1 and BRCA2 gene mutations. So far, for Iranian Breast Cancer affected Families, the Cyrillic is appropriate Software for the prediction of genetic diagnostic for BRCA1 and BRCA2. However, sample size and limitations of medical records of patients are two major limitations should be considered in future studies.
